Medhealth Review

Recent Study Highlights New Developments in Breast Cancer Treatment

There is yet another piece of news for oncologists and cancer patients. 

According to the findings of a recent clinical trial, the initial treatment given to some younger women with an aggressive version of breast cancer may soon alter.

The RIGHT Choice study was presented at the San Antonio Breast Cancer Symposium on the 6th of December. 

READ MORE: Blood Cancer Drug Blenrep from GSK to Stop in the U.S

Dr. Lu presented the study findings until April 2022 at the San Antonio meeting. Yen-Shen Lu, M.D., belongs to the National Taiwan University Hospital. 

In the experiment, a targeted medication and hormone therapy significantly outperformed standard care in slowing the growth of aggressive cancers that have already spread throughout the body.

Estrogen receptor (ER)-positive, HER2-negative breast cancer, the most prevalent form, is frequently detected early and responds favorably to treatment.

READ MORE: Cellular Technology May Improve Lung Cancer Detection

Combining ribociclib (Kisqali) and hormone therapy was more successful than usual treatment with a combination of chemotherapeutic medications at slowing the growth of metastatic tumors in pre-and perimenopausal women with breast cancer.

In five years, more than 90% of women who undergo standard treatment will still be alive and free of cancer.

“The data provide clear evidence that [the ribociclib combination] is safe, it is efficacious, and it can avoid a lot of toxicity,” Lu said.

The ribociclib combination offers another benefit, enhancing progression-free survival and having fewer side effects. In addition, both ribociclib and hormone treatment are pills that patients can take at home, unlike chemotherapy, which necessitates repeated trips to the clinic for infusions.

Must Read
Related Articles